

Appendix

Contents

| | |
|---|----|
| Codebooks | 2 |
| Codebook – Exposure, outcomes, covariates | 2 |
| Codebook – Kidney transplant | 3 |
| Codebook – Current use of medication | 4 |
| Codebook – eGFR | 4 |
| Codebook - Histopathology | 5 |
| Supplementary Tables | 6 |
| Supplementary Figures..... | 11 |

Codebooks

Codebook – Exposure, outcomes, covariates

| Condition | ICD-8 | ICD-10 |
|--|--|--|
| Exposure | | |
| Nephrotic syndrome | 581 | N04 |
| Outcomes | | |
| Arterial thromboembolism | | |
| Myocardial infarction | 410 | I21; |
| Ischemic stroke | 433-434; 436.01; 436.90 | I63; I64 |
| Other arterial thrombosis/embolism | 444 | I74; |
| Venous thromboembolism | | |
| Pulmonary embolism (PE) | 450; | I26; |
| Deep vein thrombosis (DVT) | 451.00; | I80.1-I80.3; |
| Other venous thromboembolism (VTE) | 451.01-453 | I80.0; I80.8; I80.9; I81; I82; K550H |
| Bleeding requiring hospital contact | | |
| Cerebral bleeding | 430-431; 674.99 | I60-I62 |
| Respiratory tract bleeding | 783.09; 783.19 | R04 |
| Gastrointestinal bleeding | 456.01; 530.98; 531.90; 531.92; 531.95; 532.90; 533.90; 534.90; 535.01; 784.59; 785.79; 569.15 | I85.0; K25.0; K25.2; K25.4; K25.6; K26.0; K26.2; K26.4; K26.6; K27.0; K27.2; K27.4; K27.6; K28.0; K28.2; K28.4; K28.6; K29.0; K62.5; K92.0-K92.2 |
| Urinary tract bleeding | 789.39 | R31.9; N02; N308B |
| Kidney disease (10-year lookback) | | |
| Glomerulonephritis (excl. nephrotic syndrome) | 580; 582-583 | N00-N03; N05-N08 |
| Renal tubulointerstitial disease | 590; 593.19 | N10-N16 |
| Acute kidney injury and chronic kidney disease | 792; 584 | N17-N19 |
| Cystic kidney disease | 753.10-753.19 | Q61 |
| Hypertension with nephropathy | 403-404 | I12; I13 |
| Diabetic nephropathy | 249.02; 250.02 | E102; E112; E122; E132; E142 |
| Comorbidity (10-year lookback) | | |
| Diabetes | 249; 250 | E10-E14 |
| Any connective tissue disease | 712; 716; 734; 446; 135.99 | M05; M06; M08; M09; M30; M31; M32; M33; M34; M35; M36; D86 |
| Systemic lupus erythematosus (SLE) | 734.19 | M32 |
| Sicca syndrome (Sjögren) | 734.90 | M350 |
| Amyloidosis | 267 | E85 |
| Heart failure | 427.09; 427.10; 427.11; 427.19; 428.99; 782.49 | I50; I11.0; I13.0; I13.2 |
| Chronic pulmonary disease | 490-493; 515-518 | J40-J47; J60-J67; J68.4; J70.1; J70.3; J84.1; J92.0; J96.1; J98.2; J98.3 |
| Peptic ulcer disease | 530.91; 530.98; 531-534 | K22.1; K25-K28 |
| Liver disease | 571; 573.01; 573.04; 070.00; 070.02; 070.04; 070.06; 070.08; 573.00; 456.00-456.09 | B15.0; B16.0; B16.2; B18; B19.0; K70-K74; K76.0; K76.6; I85 |
| Non-hematological cancers (excl. non-melanoma skin cancer) | 140-172, 174-199 | C00-C43, C45-C75 |

| | | |
|--|---|--|
| Hematological cancers | 200-207; 275.59 | C81-C96; D473, D752, D459, D471, D474; D46 |
| Coagulation defect | 286-287 | D65-D69 |
| Recent fracture/trauma or surgery (90-day lookback) | | |
| Recent fracture/trauma | 800-929, 950- 959 | S00-T14 |
| Recent surgery | Previous Danish Classification: 000000- 99960 | NCSP classification: KA-KQ, KX, KY |
| Ongoing pregnancy (time window depends on condition) | | |
| Pregnancy (from 280 days before to 280 days after index date) | 630-639 | O09-O49; Z32-Z36 |
| Abortion (from index date to 140 days after index date) | 640-645 | O00-O08 |
| Child delivery (from index date to 280 days after index date) | 650-662 | O60-O84; Z37-Z39 |
| History of thromboembolic or bleeding events (10-year lookback) | | |
| Arterial thromboembolism | 410; 433-434; 436.01; 436.90; 444 | I21; I63; I64; I74; |
| Venous thromboembolism | 450; 451.00; 451.01-453 | I80.1-I80.3; I80.0; I80.8; I80.9; I81; I82; K550H |
| Prior bleeding requiring hospital contact | 430-431; 674.99; 783.09; 783.19; 456.01; 530.98; 531.90; 531.92; 531.95; 532.90; 533.90; 534.90; 535.01; 784.59; 785.79; 569.15; 789.39; 280.01 | I60-I62; R04; I85.0; K25.0; K25.2; K25.4; K25.6; K26.0; K26.2; K26.4; K26.6; K27.0; K27.2; K27.4; K27.6; K28.0; K28.2; K28.4; K28.6; K29.0; K62.5; K92.0-K92.2; R31.9; N02; N308B; D62 |

Codebook – Kidney transplant

| Condition | Procedure codes | SNOMED | ICD-10 |
|-------------------|--------------------|--------|------------|
| Kidney transplant | opr57480; opr57490 | KKAS | Z940; T861 |

Codebook – Current use of medication

| Drug group | Lookback prior to NS | ATC codes include |
|-------------------------------------|----------------------|---|
| Proton pump inhibitors | 90 days | A02BC |
| Antidiabetics | 90 days | A10 |
| Any anticoagulant drugs | 90 days | B01 |
| Aspirin | 90 days | B01AC06, N02BA01, N02BA51 |
| Vitamin K antagonists | 90 days | B01AA |
| NOAC/DOAC | 90 days | B01AE, B01AF |
| Thiazides/loop diuretics | 90 days | C03AA01; C03AA03; C03AB01; C03AB03; C03AX01; C03EA; C07BA02; C07BA05; C07BA07; C07BA12; C07BA68; C07BB; C07BG; C09BA; C09DA; C09DX01; C09DX03; C09XA52; C09XA54 |
| Beta-blockers | 90 days | C07 |
| Calcium channel blockers | 90 days | C07FB; C08CA; C09BB; C09DB; C09DX01 |
| ACE-inhibitors | 90 days | C09A; C09B |
| Angiotensin-II receptor antagonists | 90 days | C09C; C09D |
| Other antihypertensives | 90 days | C02AC; C02CA; C02AB01; C03BA11; C09XA01; C09XA02; C09XA53 |
| Statins | 90 days | C10AA; C10B |
| Glucocorticoids | 90 days | H02AB |
| Antibiotics | 14 days | J01 |
| Antivirals | 14 days | J05 |
| Immunosuppressants | 90 days | L04 |
| NSAIDs | 90 days | M01A |
| Opioids | 90 days | N02A, N07BC02 |
| Antipsychotics | 90 days | N05A |
| Antidepressants | 90 days | N06A |

Codebook – eGFR

Including outpatient plasma creatinine tests taken in primary or secondary care and analyzed at hospital laboratories, i.e., excluding tests taken on dates when the patient was admitted or seen in the emergency room as recorded in the Danish National Patient Registry. For every patient, the most recent test before the index date within the time window was used.

| Biomarker | Time window | NPU code | Analysis no. |
|-------------------|-------------------------------------|--|---|
| Plasma creatinine | 365 days to 1 day before index date | ASS00354, ASS00355, ASS00356, NPU01807, NPU04998, NPU09101, NPU17559, NPU18016, AAB00327 | 38926, 38927, 38928, 110266, 1511235, 1511236, 1610154, 1611807, 1710301, 1711807, 1811807, 1817156, 1155, 111016, 1311235, 1411235, 1511237, 1610296, 1710552, 1817428, 716, 1155, 1807, 4998, 18016, 38927, 110266, 111016, 1311235, 1411235, 1511235, 1511236, 1511237, 1610154, 1610296, 1611807, 1710301, 1710552, 1711807, 1811807, 1817156, 1817428 |

Codebook - Histopathology

Codes retrieved from Patobank: <https://www.patobank.dk/kodebog/?tag=M>

| Group to report | Type of glomerulonephritis | Pathological description | Code descrip. | Code tissue |
|---|--|---|---------------|-------------|
| Membranous nephropathy (MN) | Membranous nephropathy | Membranous glomerulonephritis | M68130 | T71 |
| Membranoproliferative glomerulonephritis (MPGN) | Membranoproliferative glomerulonephritis | Membranoproliferative glomerulonephritis | M46842 | T71 |
| | | Dense deposit disease | M46844 | T71 |
| Other proliferative glomerulonephritis | Mesangioproliferative glomerulopathy | Mesangioproliferative glomerulonephritis | M46862 | T71 |
| | | IgA-glomerulonephritis | S67300 | T71 |
| | Proliferative endocapillary glomerulonephritis | Endocapillary proliferative glomerulonephritis | M46870 | T71 |
| | | Post-infectious glomerulonephritis | S67410 | T71 |
| Unspecified proliferative GN | Proliferative glomerulonephritis | M46810 | T71 | |
| Focal segmental glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis | Focal segmental glomerulosclerosis | M53341 | T71 |
| | | Focal segmental glomerulosclerosis, cellular type | M53342 | T71 |
| | | Focal segmental glomerulosclerosis, collapsing type | M53343 | T71 |
| | | Focal segmental glomerulosclerosis, tip lesion | M53344 | T71 |
| Minimal change disease (MCD) | Minimal change disease | Normal tissue | M00100 | T71 |
| | | Minimal change disease | S67550 | T71 |
| | | Foot process fusion | M53440 | T71 |
| | | | | |
| Other histopathology | Diabetic nephropathy | Diabetic nephropathy | S67700 | T71 |
| | | Nodular intercapillary glomerulosclerosis | M53320 | T71 |
| | Deposition glomerulonephritis | Amyloid deposit | M55100 | T71 |
| | | Light chain cast disease | M55120 | T71 |
| | | Light chain deposit disease | M55130 | T71 |
| | | Fibrillary glomerulonephritis | M55170 | T71 |
| | | Immunotactoid glomerulopathy | M55180 | T71 |
| | | Fibronectin glomerulopathy | M55190 | T71 |
| | | AA amyloidosis | S38930 | T71 |
| | | AL amyloidosis | S38940 | T71 |
| | Necrotizing and crescentic glomerulonephritis and vasculitis (extracapillary glomerulonephritis) | Extracapillary glomerulonephritis | M46880 | T71 |
| | | Wegener's granulomatosis | S76950 | T71 |
| | | ANCA-associated glomerulonephritis | S67420 | T71 |
| | | Anti-GBM glomerulonephritis | S67400 | T71 |
| | Hypertensive nephropathy and thrombotic microangiopathies | Arteriolosclerosis with fibrinoid necrosis | M52210 | T71 |
| | | Hyaline arteriolosclerosis | M52250 | T71 |
| | | Thrombotic microangiopathy | M53420 | T71 |
| | | Hemolytic, uremic syndrome | S42940 | T71 |
| | Other/unspecified glomerulonephritis and fibrosis | Focal glomerulonephritis | M46861 | T71 |
| | | Glomerulonephritis NOS | M46801 | T71 |
| | | Glomerular half-moon | M4680A | T71 |
| | | Glomerulosclerosis | M53300 | T71 |
| | | Diffuse intercapillary glomerulosclerosis | M53312 | T71 |
| | | Focal segmental proliferative glomerulonephritis | M46811 | T71 |
| | | Fibrosis | M49000 | T71 |
| | Non-glomerular conditions (interstitial and/or tubular inflammation/necrosis) | Acute and chronic inflammation | M42100 | T71 |
| | | Chronic inflammation | M43000 | T71 |
| | | Follicular inflammation | M43080 | T71 |
| | | Non-necrotizing granulomatous inflammation | M44200 | T71 |
| | | Granulation tissue | M45020 | T71 |
| | | Ischemia-reperfusion injury | M52700 | T71 |
| | | Acute ischemic nephropathy | M53150 | T71 |
| Acute tubular damage | | M53160 | T71 | |
| Ischemic acute tubular necrosis | | S67630 | T71 | |
| IgG4-related disease | | S47414 | T71 | |

Supplementary Tables

Suppl. Table 1. Characteristics of patients by type of histopathology 180 days after the index date among 1,902 patients with first-time hospital-recorded NS and a kidney biopsy.

| Characteristics | Membranous nephropathy (MN) (n=455) | Membranoproliferative glomerulonephritis (MPGN) (n=108) | Other proliferative glomerulonephritis (n=303) | Focal segmental glomerulonephritis (FSGS) (n=163) | Minimal change disease (MCD) (n=468) | Other histopathology (n=405) |
|---|-------------------------------------|---|--|---|--------------------------------------|------------------------------|
| Female sex | 168 (37%) | 58 (54%) | 124 (41%) | 60 (37%) | 208 (44%) | 146 (36%) |
| Age group | | | | | | |
| 18-29 years | 27 (6%) | 12 (11%) | 60 (20%) | 18 (11%) | 66 (14%) | 25 (6%) |
| 30-39 years | 54 (12%) | 10 (9%) | 43 (14%) | 22 (13%) | 69 (15%) | 30 (7%) |
| 40-49 years | 58 (13%) | 24 (22%) | 54 (18%) | 28 (17%) | 76 (16%) | 45 (11%) |
| 50-59 years | 99 (22%) | 26 (24%) | 47 (16%) | 30 (18%) | 77 (16%) | 88 (22%) |
| 60-69 years | 119 (26%) | 19 (18%) | 53 (17%) | 28 (17%) | 101 (22%) | 110 (27%) |
| 70-79 years | 79 (17%) | 12 (11%) | 40 (13%) | 25 (15%) | 62 (13%) | 84 (21%) |
| 80+ years | 19 (4%) | 5 (5%) | 6 (2%) | 12 (7%) | 17 (4%) | 23 (6%) |
| Calendar period | | | | | | |
| 1995-1999 | 59 (13%) | 9 (9%) | 46 (15%) | 13 (8%) | 50 (11%) | 53 (13%) |
| 2000-2005 | 115 (26%) | 29 (28%) | 64 (21%) | 31 (19%) | 108 (23%) | 100 (25%) |
| 2006-2011 | 108 (24%) | 24 (23%) | 70 (23%) | 51 (31%) | 133 (29%) | 88 (22%) |
| 2012-2018 | 164 (37%) | 43 (41%) | 118 (40%) | 67 (41%) | 173 (37%) | 154 (39%) |
| Kidney disease diagnosed in hospital up to 10 years before 180 days after index date | | | | | | |
| Glomerulonephritis (excl. nephrotic syndrome) | 215 (47%) | 67 (62%) | 171 (56%) | 56 (34%) | 167 (36%) | 98 (24%) |
| Renal tubulointerstitial disease | 16 (4%) | 6 (6%) | 12 (4%) | 6 (4%) | 15 (3%) | 26 (6%) |
| Acute kidney injury or chronic kidney disease | 80 (18%) | 45 (42%) | 101 (33%) | 53 (33%) | 86 (18%) | 161 (40%) |
| Cystic kidney disease | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) |
| Hypertension with nephropathy | 14 (3%) | 7 (6%) | 8 (3%) | 7 (4%) | 10 (2%) | 17 (4%) |
| Diabetic nephropathy | 6 (1%) | < 5 (-) | 17 (6%) | 5 (3%) | 13 (3%) | 102 (25%) |
| Comorbidity diagnosed in hospital up to 10 years before 180 days after index date | | | | | | |
| Diabetes | 30 (7%) | 9 (8%) | 32 (11%) | 21 (13%) | 48 (10%) | 147 (36%) |
| Any connective tissue disease | 46 (10%) | 19 (18%) | 37 (12%) | 8 (5%) | 26 (6%) | 40 (10%) |
| Systemic lupus erythematosus (SLE) | 21 (5%) | 8 (7%) | 20 (7%) | < 5 (-) | 6 (1%) | 7 (2%) |
| Sicca syndrome (Sjögren) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) |
| Amyloidosis | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | 6 (1%) | 108 (27%) |
| Heart failure | 26 (6%) | 12 (11%) | 18 (6%) | 8 (5%) | 19 (4%) | 46 (11%) |
| Chronic pulmonary disease | 44 (10%) | 14 (13%) | 29 (10%) | 9 (6%) | 41 (9%) | 38 (9%) |
| Peptic ulcer disease | 10 (2%) | 6 (6%) | 7 (2%) | < 5 (-) | 15 (3%) | 20 (5%) |
| Liver disease | < 5 (-) | 8 (7%) | < 5 (-) | 5 (3%) | 9 (2%) | 13 (3%) |
| Non-hematological cancer | 44 (10%) | < 5 (-) | 13 (4%) | 12 (7%) | 31 (7%) | 31 (8%) |
| Hematological cancer | 16 (4%) | 10 (9%) | 17 (6%) | < 5 (-) | 20 (4%) | 55 (14%) |

| | | | | | | |
|---|--------------|--------------|--------------|--------------|---------------|--------------|
| Coagulation defect | 10 (2%) | < 5 (-) | 19 (6%) | < 5 (-) | 8 (2%) | 8 (2%) |
| Ongoing pregnancy | < 5 (-) | < 5 (-) | 9 (3%) | < 5 (-) | 9 (2%) | < 5 (-) |
| Recent fracture/trauma | 5 (1%) | < 5 (-) | 7 (2%) | 5 (3%) | 13 (3%) | 14 (3%) |
| Recent surgery | 45 (10%) | 19 (18%) | 30 (10%) | 23 (14%) | 34 (7%) | 84 (21%) |
| Most recent eGFR | | | | | | |
| Median eGFR ml/min/1.73 m ² [IQR] | 67 [48 - 90] | 39 [21 - 67] | 48 [28 - 71] | 53 [32 - 78] | 84 [66 - 101] | 42 [25 - 67] |
| Missing eGFR* | 312 (69%) | 76 (70%) | 195 (64%) | 107 (66%) | 320 (68%) | 284 (70%) |
| History of thromboembolic or bleeding events up to 10 years before 180 days after index date | | | | | | |
| Prior thromboembolic event | 79 (17%) | 21 (19%) | 39 (13%) | 20 (12%) | 49 (10%) | 63 (16%) |
| Prior bleeding requiring hospital contact | 49 (11%) | 28 (26%) | 49 (16%) | 26 (16%) | 40 (9%) | 71 (18%) |
| Current use of medication 180 days after index date | | | | | | |
| Proton pump inhibitors** | 173 (38%) | 49 (45%) | 103 (34%) | 61 (37%) | 198 (42%) | 122 (30%) |
| Antidiabetics** | 32 (7%) | 6 (6%) | 25 (8%) | 13 (8%) | 29 (6%) | 110 (27%) |
| Any anticoagulant drug** | 137 (30%) | 30 (28%) | 61 (20%) | 47 (29%) | 68 (15%) | 97 (24%) |
| Aspirin** | 50 (11%) | 13 (12%) | 31 (10%) | 21 (13%) | 35 (7%) | 59 (15%) |
| Vitamin K antagonists** | 73 (16%) | 12 (11%) | 23 (8%) | 14 (9%) | 24 (5%) | 30 (7%) |
| NOACs/DOACs** | 7 (2%) | < 5 (-) | < 5 (-) | 7 (4%) | < 5 (-) | < 5 (-) |
| Thiazides/loop diuretics** | 57 (13%) | 10 (9%) | 29 (10%) | 31 (19%) | 38 (8%) | 46 (11%) |
| Beta-blockers** | 78 (17%) | 32 (30%) | 73 (24%) | 44 (27%) | 72 (15%) | 104 (26%) |
| Calcium channel blockers** | 78 (17%) | 30 (28%) | 64 (21%) | 39 (24%) | 51 (11%) | 96 (24%) |
| ACE-inhibitors** | 244 (54%) | 47 (44%) | 143 (47%) | 78 (48%) | 156 (33%) | 144 (36%) |
| Angiotensin-II receptor antagonists** | 130 (29%) | 20 (19%) | 65 (21%) | 54 (33%) | 54 (12%) | 77 (19%) |
| Other antihypertensives | 9 (2%) | < 5 (-) | 5 (2%) | 9 (6%) | 8 (2%) | 16 (4%) |
| Statins** | 177 (39%) | 16 (15%) | 64 (21%) | 58 (36%) | 99 (21%) | 110 (27%) |
| Glucocorticoids** | 129 (28%) | 28 (26%) | 83 (27%) | 35 (21%) | 196 (42%) | 67 (17%) |
| Antibiotics*** | 12 (3%) | 5 (5%) | 11 (4%) | 6 (4%) | 14 (3%) | 15 (4%) |
| Antivirals*** | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) | < 5 (-) |
| Immunosuppressants** | 23 (5%) | < 5 (-) | 13 (4%) | 9 (6%) | 21 (4%) | 15 (4%) |
| NSAIDs** | 18 (4%) | < 5 (-) | 10 (3%) | 7 (4%) | 18 (4%) | 20 (5%) |
| Opioids** | 46 (10%) | < 5 (-) | 20 (7%) | 13 (8%) | 37 (8%) | 57 (14%) |
| Antipsychotics** | < 5 (-) | < 5 (-) | 5 (2%) | < 5 (-) | 12 (3%) | 6 (1%) |
| Antidepressants** | 23 (5%) | 6 (6%) | 18 (6%) | 14 (9%) | 32 (7%) | 35 (9%) |

Values are given as n (%) unless otherwise noted. Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; NOAC, novel oral anticoagulant; DOAC, direct oral anticoagulant; ACE, angiotensin converting enzyme; NSAID, non-steroidal anti-inflammatory drug

* Missing eGFR may be due to incomplete coverage, as complete nationwide coverage of laboratory data was not achieved before 2014.

** Prescriptions filled 90 days before day 180 after the index date.

*** Prescriptions filled during the 14 days before day 180 after the index date.

Suppl. Table 2. Risk of any thromboembolic or bleeding events (%) during days 0-180 from the NS index date among patients with kidney biopsy.

| | Arterial thromboembolism | | Venous thromboembolism | | Bleeding | |
|---|--------------------------|------------------|------------------------|------------------|------------|------------------|
| | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) |
| Type of glomerulonephritis ^{a,b} | | | | | | |
| Membranous nephropathy (MN) | 14 | 3.1 (1.8 - 5.0) | 14 | 3.1 (1.8 - 5.0) | 14 | 3.1 (1.8 - 5.0) |
| Membranoproliferative glomerulonephritis (MPGN) | 7 | 6.5 (2.8 - 12.2) | < 5 | - | <10 | - |
| Other proliferative glomerulonephritis | <10 | - | 9 | 3.0 (1.5 - 5.4) | 14 | 4.6 (2.7 - 7.4) |
| Focal segmental glomerulosclerosis (FSGS) | < 5 | - | < 5 | - | < 5 | - |
| Minimal change disease (MCD) | 10 | 2.1 (1.1 - 3.8) | 15 | 3.2 (1.9 - 5.1) | <10 | - |
| Other histopathology | 14 | 3.5 (2.0 - 5.6) | 7 | 1.7 (0.8 - 3.4) | 17 | 4.2 (2.6 - 6.6) |

Abbreviations: CI, confidence interval;

^a Each person was included with a maximum of one type of histopathological finding. In case of several biopsies in the same patient \pm 180 days from the NS index date, the biopsy closest to the NS index date was used, and in the case of several findings in the same biopsy, the finding listed highest in the codebook was used.

^b In groups with fewer than 5 events, the number is masked with “<5” due to Danish legislation. To prevent calculating the exact number from a total sum, other low number(s) may also be masked.

Suppl. Table 3. Ten-year risk of ATE, VTE and bleeding (%) among patients with nephrotic syndrome (NS) by kidney disease or comorbidity diagnosed prior to the NS index date.

| | Arterial thromboembolism | | Venous thromboembolism | | Bleeding | |
|--|--------------------------|--------------------|------------------------|-------------------|------------|--------------------|
| | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) |
| Kidney disease diagnosed in hospital up to 10 years before index date^a | | | | | | |
| Glomerulonephritis (excl. nephrotic syndrome) | 65 | 14.2 (11.2 - 17.7) | 27 | 6.3 (4.2 - 8.9) | 65 | 14.4 (11.3 - 17.9) |
| Renal tubulointerstitial disease | 24 | 15.6 (10.2 - 22.0) | 10 | 6.2 (3.1 - 10.7) | 25 | 15.0 (10.0 - 20.9) |
| Acute kidney injury or chronic kidney disease | 100 | 20.5 (16.9 - 24.4) | 31 | 6.7 (4.6 - 9.4) | 115 | 23.4 (19.6 - 27.4) |
| Cystic kidney disease | 20 | 25.1 (16.0 - 35.2) | < 5 | - | < 5 | - |
| Hypertension with nephropathy | 65 | 14.2 (11.2 - 17.7) | 6 | 7.6 (3.0 - 14.9) | 16 | 20.8 (12.3 - 30.8) |
| Diabetic nephropathy | 39 | 22.5 (16.3 - 29.3) | 10 | 5.5 (2.7 - 9.6) | 38 | 21.6 (15.5 - 28.4) |
| Comorbidity diagnosed in hospital up to 10 years before index date^a | | | | | | |
| Diabetes | 113 | 22.9 (19.1 - 26.9) | 32 | 6.7 (4.6 - 9.4) | 106 | 21.9 (18.2 - 25.8) |
| Any connective tissue disease | 35 | 16.1 (11.5 - 21.5) | 25 | 11.8 (7.9 - 16.7) | 33 | 15.3 (10.8 - 20.6) |
| Systemic lupus erythematosus (SLE) | 9 | 18.6 (9.0 - 30.8) | 7 | 15.3 (6.6 - 27.5) | 7 | 14.6 (6.3 - 26.1) |
| Sicca syndrome (Sjögren) | < 5 | - | < 5 | - | < 5 | - |
| Amyloidosis | < 5 | - | 16 | 5.1 (3.0 - 8.0) | < 5 | - |
| Heart failure | 49 | 16.6 (12.6 - 21.2) | 31 | 9.6 (6.6 - 13.1) | 48 | 16.4 (12.3 - 20.9) |
| Chronic pulmonary disease | 46 | 14.6 (10.9 - 18.9) | 6 | 4.6 (1.9 - 9.3) | 58 | 18.6 (14.4 - 23.2) |
| Peptic ulcer disease | 20 | 16.4 (10.3 - 23.6) | < 5 | - | 35 | 26.4 (19.1 - 34.2) |
| Liver disease | 9 | 15.8 (7.2 - 27.5) | 20 | 9.7 (6.1 - 14.3) | 13 | 18.1 (9.8 - 28.4) |
| Non-hematological cancer | 36 | 17.0 (12.1 - 22.7) | 12 | 11.9 (6.3 - 19.4) | 35 | 17.7 (12.5 - 23.6) |
| Hematological cancer | 16 | 15.1 (8.9 - 22.9) | 8 | 12.8 (5.8 - 22.6) | 17 | 15.9 (9.4 - 23.9) |
| Coagulation defect | 7 | 11.5 (4.9 - 21.2) | 25 | 11.8 (7.9 - 16.7) | 15 | 23.1 (13.5 - 34.2) |

Abbreviations: CI, confidence interval;


^a In groups with fewer than 5 events, the number is masked with “<5” due to Danish legislation. To prevent calculating the exact number from a total sum, other low number(s) may also be masked.

Suppl. Table 4. Ten-year risk of thromboembolism and bleeding among 875 patients with hospital-recorded nephrotic syndrome and an available outpatient eGFR (ml/min/1.73 m²) during the 365 days before the index date, stratified by CKD stage.


| CKD stage at index date | Arterial thromboembolism | | Venous thromboembolism | | Bleeding | |
|-------------------------|--------------------------|--------------------|------------------------|------------------|------------|------------------|
| | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) | No. events | Risk, % (95% CI) |
| 1 or 2 (eGFR ≥60) | 34 | 8.8 (6.2 - 12.0) | 28 | 6.7 (4.5 - 9.5) | 53 | 13.8 (10.4-17.6) |
| 3a (eGFR 45-59) | 10 | 10.8 (5.4 - 18.3) | 5 | 5.6 (2.0 - 11.9) | 17 | 17.2 (10.4-25.4) |
| 3b (eGFR 30-44) | 13 | 15.2 (8.1 - 24.3) | 7 | 6.0 (2.6 - 11.4) | 16 | 16.5 (9.6-25.1) |
| 4 (eGFR 15-29) | 16 | 16.9 (9.9 - 25.4) | 8 | 9.0 (4.0 - 16.4) | 22 | 24.6 (15.9-34.3) |
| 5 (eGFR <15) | 10 | 29.0 (14.3 - 45.4) | < 5 | - | 7 | 21.0 (7.5-39.0) |

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate;

Supplementary Figures



Suppl. Figure 1. Flowchart of inclusion, matching, and censoring



Suppl. Figure 2. Ten-year risk of first-time arterial thromboembolism (left), venous thromboembolism (center) and bleeding (right) in patients with nephrotic syndrome and individuals from the general population (matched for age and sex) without prior ATE, VTE, and bleeding events, respectively.